Increasing Demand For Personalized Medicines Drive The Global Oncology Drugs Market (Companies Included: Novartis AG, F. Hoffmann-La Roche Ltd., Allergan Plc., Valeant Pharmaceuticals Intl Inc., Bayer AG)

Oncology deals with diagnosis, prevention and treatment of cancer diseases. Anti-cancer or anti-neoplastic agents are the drugs that prevent or inhibit or halt the proliferation and maturation of neoplasms,...

Oncology deals with diagnosis, prevention and treatment of cancer diseases. Anti-cancer or anti-neoplastic agents are the drugs that prevent or inhibit or halt the proliferation and maturation of neoplasms, an abnormal growth of tissues commonly referred as tumors. These drugs prevent the growth of malignant tumors by affecting the process of cell division or by damaging the DNA and initiate apoptosis or by preventing the development and spread of neoplastic cells. Several types of cancers that can be treated by oncology drugs are blood cancer, lung cancer, endocrine cancer, bone cancer, gastric cancer, colorectal cancer, skin cancer, breast cancer, pancreatic cancer, prostate cancers, ovarian cancer, ocular cancer and others

Order report at:

https://www.thebusinessresearchcompany.com/report/oncology-drugs-global-market-report-2018

The global oncology drugs market has shown modest growth in the past years with a CAGR of over 8.8%. The year 2017 recorded highest ever growth in this market with a net value of $125.9 billion as per TBRC’s in-house consultants.

TBRC’s latest report shows the historic and future trends in the market for each year with sourced reasons to support the growth claims.

The report also shows the oncology drugs market to grow at a higher CAGR by 2021 as compared to 2017, along with geographies best suited for investments with highest return rate.

Download sample report at

https://www.thebusinessresearchcompany.com/sample.aspx?id=280&type=smp

Personalized medicines have a tremendous impact on cancer treatment as they provide a customized individual treatment where chemotherapy fails to achieve the desired patient outcomes. The idea of personalized medicine, also referred to as precision medicine, is to provide medical care according to the patient’s individual characteristics, needs, preferences and genetic makeup. Several companies are investing in this type of medicines. According to a survey by the Tufts Center, 94% of pharmaceutical companies are investing in personalized medicine research. For instance, Kura Oncology Inc., a biopharmaceutical company, is developing a pipeline of precision medicines for the treatment of solid tumors and blood cancers. Perthera, a US based company is also developing in personalized cancer therapies

TBRC’s latest report will cover in depth understanding and calculated impacts of each market factor on a global as well as regional level, to analyze the best investment strategy for this market.

Companies included in the report are Novartis AG, F. Hoffmann-La Roche Ltd., Allergan Plc., Valeant Pharmaceuticals Intl Inc., and Bayer AG.

About The Business Research Company.

The Business Research Company is a Business Intelligence Company which excels in company, market and consumer research. It has offices in the UK, the US and India and a network of trained researchers in 15 countries globally.

Contact Information

The Business Research Company

Europe: +44 207 1930 708

Asia: +91 8897263534

Americas: +1 315 623 0293

Email: [email protected]

Follow us on Linkedin: https://in.linkedin.com/company/the-business-research-company

 

 

 

Categories
Drug
No Comment

Leave a Reply

*

*